Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Editorial
25 January 2017

The comparative effectiveness of antiretroviral therapies for HIV: evidence to inform precision public health

Authors: Edward J Mills [email protected], Steve Kanters, and Nathan FordAuthor Info & Affiliations
Publication: J. Comp. Eff. Res.
Volume 6, Number 2
https://doi.org/10.2217/cer-2016-0093
PDFFormats
First page of PDF

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

1.
Wang H, Wolock TM, Carter A et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV 3(8), E361–E387 (2016).
PubMed
Google Scholar
2.
Murray CJ, Ortblad KF, Guinovart C et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9947), 1005–1070 (2014).
PubMed
Google Scholar
3.
Kent DM, Mwamburi DM, Bennish ML et al. Clinical trials in sub-Saharan Africa and established standards of care: a systematic review of HIV, tuberculosis, and malaria trials. JAMA 292(2), 237–242 (2004).
PubMed
Google Scholar
4.
UNAIDS. Fact sheet, November 2016. www.unaids.org/en/resources/fact-sheet
Google Scholar
5.
Gunthard HF, Saag MS, Benson CA et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA 316(2), 191–210 (2016).
PubMed
Google Scholar
6.
Kanters S, Ford N, Druyts E et al. Use of network meta-analysis in clinical guidelines. Bull. WHO 94(10), 782–784 (2016).
PubMed
Google Scholar
7.
WHO. Global update on HIV treatment 2013: results, impact and opportunities (2013). www.who.int/hiv/pub/progressreports/update2013/en/
Google Scholar
8.
Doherty M, Ford N, Vitoria M et al. The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities. Curr. Opin. HIV AIDS 8(6), 528–534 (2013).
PubMed
Google Scholar
9.
Mesplède T, Quashie PK, Zanichelli V et al. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann. Med. 46(3), 123–129 (2014).
PubMed
Google Scholar
10.
Raffi F, Jaeger H, Quiros-Roldan E et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect. Dis. 13(11), 927–935 (2013).
PubMed
Google Scholar
11.
Walmsley SL, Antela A, Clumeck N et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N. Engl. J. Med. 369(19), 1807–1818 (2013).
PubMed
Google Scholar
12.
Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ 346, f2914 (2013).
PubMed
Google Scholar
13.
Kanters S, Vitoria M, Doherty M et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV 3(11), E510–E520 (2016).
PubMed
Google Scholar
14.
Pozniak AL, Hill AM. First-line integrase inhibitors for HIV-prices versus benefits. Lancet HIV 3(11), E500–E501 (2016).
PubMed
Google Scholar
15.
Dowell SF, Blazes D, Desmond-Hellman S. Four steps to precision public health. Nature 540, 189–191 (2016).
Google Scholar
|